SCHEMBL17816104

SCHEMBL17816104

O=C(Nc1ccc(F)c(Cl)c1)c1ccc(I)c(S[C@@H]2CCC[C@@H](O)C2)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 2/20 0.47
RAB9A P51151 2/20 0.47
KCNQ3 O43525 1/20 0.44
KCNQ2 O43526 1/20 0.44
KCNE1 P15382 1/20 0.44
KCNQ1 P51787 1/20 0.44
NPSR1 Q6W5P4 1/20 0.43
MAOB P27338 4/20 0.42
MAPT P10636 1/20 0.42
MEN1 O00255 1/20 0.42
ALDH1A1 P00352 1/20 0.42
KMT2A Q03164 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.41
MAOA P21397 2/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
CHRM1 P11229 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
TP53 P04637 1/20 0.40
POLB P06746 1/20 0.40
CCR2 P41597 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17816113 0.98 NPC1 (0.47) NPC1RAB9AKCNQ3KCNQ2KCNE1
SCHEMBL17816127 0.98 NPC1 (0.47) NPC1RAB9AKCNQ3KCNQ2KCNE1
SCHEMBL17816115 0.94 NPC1 (0.48) NPC1RAB9AKCNQ3KCNQ2KCNE1
SCHEMBL17795725 0.92 NPC1 (0.50) NPC1RAB9AKCNQ3KCNQ2KCNE1
SCHEMBL17792087 0.92 NPC1 (0.50) NPC1RAB9AKCNQ3KCNQ2KCNE1
SCHEMBL17784136 0.92 NPC1 (0.50) NPC1RAB9AKCNQ3KCNQ2KCNE1
SCHEMBL17792160 0.92 NPC1 (0.50) NPC1RAB9AKCNQ3KCNQ2KCNE1
SCHEMBL17784104 0.90 NPC1 (0.50) NPC1RAB9AKCNQ3KCNQ2KCNE1
SCHEMBL17792163 0.90 NPC1 (0.50) NPC1RAB9AKCNQ3KCNQ2KCNE1
SCHEMBL17792094 0.90 NPC1 (0.50) NPC1RAB9AKCNQ3KCNQ2KCNE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2016089990-A1 SULFIDE ALKYL AND PYRIDYL REVERSE SULFONAMIDE COMPOUNDS FOR HBV TREATMENT NOVIRA THERAPEUTICS, INC. (US) 2016-06-09 WO disclosed